Top

Published in:

Open Access 01-12-2015 | Research

Tau phosphorylation regulates the interaction between BIN1’s SH3 domain and Tau’s proline-rich domain

Authors: Yoann Sottejeau, Alexis Bretteville, François-Xavier Cantrelle, Nicolas Malmanche, Florie Demiaute, Tiago Mendes, Charlotte Delay, Harmony Alves Dos Alves, Amandine Flaig, Peter Davies, Pierre Dourlen, Bart Dermaut, Jocelyn Laporte, Philippe Amouyel, Guy Lippens, Julien Chapuis, Isabelle Landrieu, Jean-Charles Lambert

Published in: Acta Neuropathologica Communications | Issue 1/2015

Abstract

Introduction

The application of high-throughput genomic approaches has revealed 24 novel risk loci for Alzheimer’s disease (AD). We recently reported that the bridging integrator 1 (BIN1) risk gene is linked to Tau pathology.

Results

We used glutathione S-transferase pull-down assays and nuclear magnetic resonance (NMR) experiments to demonstrate that BIN1 and Tau proteins interact directly and then map the interaction between BIN1’s SH3 domain and Tau’s proline-rich domain (PRD) . Our NMR data showed that Tau phosphorylation at Thr231 weakens the SH3-PRD interaction. Using primary neurons, we found that BIN1-Tau complexes partly co-localize with the actin cytoskeleton; however, these complexes were not observed with Thr231-phosphorylated Tau species.

Conclusion

Our results show that (i) BIN1 and Tau bind through an SH3-PRD interaction and (ii) the interaction is downregulated by phosphorylation of Tau Thr231 (and potentially other residues). Our study sheds new light on regulation of the BIN1/Tau interaction and opens up new avenues for exploring its complex’s role in the pathogenesis of AD.

Available only for authorised users

Hardy JA, Higgins GA (1992) Alzheimer’s disease. the amyloid cascade hypothesis 256:184–185. doi:10.1126/science.1566067

Genin E, Hannequin D, Wallon D, Sleegers K, Hiltunen M, Combarros O, Bullido MJ, Engelborghs S, De Deyn P, Berr C, Pasquier F, Dubois B, Tognoni G, Fiévet N, Brouwers N, Bettens K, Arosio B, Coto E, Del Zompo M, Mateo I, Epelbaum J, Frank-Garcia A, Helisalmi S, Porcellini E, Pilotto A, Forti P, Ferri R, Scarpini E, Siciliano G, Solfrizzi V et al (2011) APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry 16:903–907. doi:10.1038/mp.2011.52 PubMedCentralCrossRefPubMed

Chapuis J, Hansmannel F, Gistelinck M, Mounier A, Van Cauwenberghe C, Kolen KV, Geller F, Sottejeau Y, Harold D, Dourlen P, Grenier-Boley B, Kamatani Y, Delepine B, Demiautte F, Zelenika D, Zommer N, Hamdane M, Bellenguez C, Dartigues J-F, Hauw J-J, Letronne F, Ayral A-M, Sleegers K, Schellens A, Broeck LV, Engelborghs S, De Deyn PP, Vandenberghe R, O’Donovan M, Owen M et al (2013) Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology. Mol Psychiatry 18:1225–1234. doi:10.1038/mp.2013.1 PubMedCentralCrossRefPubMed

Nicot A-S, Toussaint A, Tosch V, Kretz C, Wallgren-Pettersson C, Iwarsson E, Kingston H, Garnier J-M, Biancalana V, Oldfors A, Mandel J-L, Laporte J (2007) Mutations in amphiphysin 2 (BIN1) disrupt interaction with dynamin 2 and cause autosomal recessive centronuclear myopathy. Nat Genet 39:1134–1139. doi:10.1038/ng2086 CrossRefPubMed

Amniai L, Barbier P, Sillen A, Wieruszeski J-M, Peyrot V, Lippens G, Landrieu I (2009) Alzheimer disease specific phosphoepitopes of Tau interfere with assembly of tubulin but not binding to microtubules. FASEB J 23:1146–1152. doi:10.1096/fj.08-121590 CrossRefPubMed

Weaver CL, Espinoza M, Kress Y, Davies P (2000) Conformational change as one of the earliest alterations of tau in Alzheimer’s disease. Neurobiol Aging 21:719–727. doi:10.1016/S0197-4580(00)00157-3 CrossRefPubMed

Vingtdeux V, Davies P, Dickson DW, Marambaud P (2011) AMPK is abnormally activated in tangle-and pre-tangle-bearing neurons in Alzheimer’s disease and other tauopathies. Acta Neuropathol 121:337–349. doi:10.1007/s00401-010-0759-x PubMedCentralCrossRefPubMed

Otvos L, Feiner L, Lang E, Szendrei GI, Goedert M, Lee VMY (1994) Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res 39:669–673. doi:10.1002/jnr.490390607 CrossRefPubMed

Morel E, Chamoun Z, Lasiecka ZM, Chan RB, Williamson RL, Vetanovetz C, Dall’Armi C, Simoes S, Point Du Jour KS, McCabe BD, Small SA, Di Paolo G (2013) Phosphatidylinositol-3-phosphate regulates sorting and processing of amyloid precursor protein through the endosomal system. Nat Commun 4:2250. doi:10.1038/ncomms3250 PubMedCentralCrossRefPubMed

10.

Lippens G, Sillen A, Smet C, Wieruszeski J-M, Leroy A, Buée L, Landrieu I (2006) Studying the natively unfolded neuronal Tau protein by solution NMR spectroscopy. Protein Pept Lett 13:235–246CrossRefPubMed

11.

Reynolds CH, Garwood CJ, Wray S, Price C, Kellie S, Perera T, Zvelebil M, Yang A, Sheppard PW, Varndell IM, Hanger DP, Anderton BH (2008) Phosphorylation regulates tau interactions with Src homology 3 domains of phosphatidylinositol 3-kinase, phospholipase Cgamma1, Grb2, and Src family kinases. J Biol Chem 283:18177–18186. doi:10.1074/jbc.M709715200 CrossRefPubMed

12.

Pooler AM, Usardi A, Evans CJ, Philpott KL, Noble W, Hanger DP (2012) Dynamic association of tau with neuronal membranes is regulated by phosphorylation. Neurobiol Aging 431(33):e27–38. doi:10.1016/j.neurobiolaging.2011.01.005

13.

Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, DeStafano AL, Bis JC, Beecham GW, Granier-Boley B, Russo G, Thorton-Wells TA, Jones N, Smith AV, Chouraki V, Thomas C, Ikram MA, Zelenika D, Vardarajan BN, Kamatani Y, Lin CF, Gerrish A, Schmidt H, Kunkle B, Dunstan ML, Ruiz A, Bihoreau MT, Choi SH, Reitz C, Pasquier F et al (2013) Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet 45:1452–8. doi:10.1038/ng.2802 PubMedCentralCrossRefPubMed

14.

Prokic I, Cowling BS, Laporte J (2014) Amphiphysin 2 (BIN1) in physiology and diseases. J Mol Med 2:1–11. doi:10.1007/s00109-014-1138-1

15.

Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW (1975) A protein factor essential for microtubule assembly. Proc Natl Acad Sci U S A 72:1858–1862. doi:10.1073/pnas.72.5.1858 PubMedCentralCrossRefPubMed

16.

Lee G, Newman ST, Gard DL, Band H, Panchamoorthy G (1998) Tau interacts with src-family non-receptor tyrosine kinases. J Cell Sci 111(Pt 2):3167–3177PubMed

17.

Lee G (2005) Tau and src family tyrosine kinases. Biochim Biophys Acta, Mol Basis Dis 1739:323–330. doi:10.1016/j.bbadis.2004.09.002 CrossRef

18.

Bhaskar K, Yen SH, Lee G (2005) Disease-related modifications in tau affect the interaction between Fyn and tau. J Biol Chem 280:35119–35125. doi:10.1074/jbc.M505895200 CrossRefPubMed

19.

Smith CJ, Anderton BH, Davis DR, Gallo JM (1995) Tau isoform expression and phosphorylation state during differentiation of cultured neuronal cells. FEBS Lett 375:243–248CrossRefPubMed

20.

Maas T, Eidenmuller J, Brandt R (2000) Interaction of tau with the neural membrane cortex is regulated by phosphorylation at sites that are modified in paired helical filaments. J Biol Chem 275:15733–15740. doi:10.1074/jbc.M000389200, M000389200 [pii]CrossRefPubMed

21.

Augustinack JC, Schneider A, Mandelkow EM, Hyman BT (2002) Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer’s disease. Acta Neuropathol 103:26–35. doi:10.1007/s004010100423 CrossRefPubMed

22.

Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH (1999) Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402:615–622. doi:10.1038/45159 CrossRefPubMed

23.

Leroy K, Boutajangout A, Authelet M, Woodgett JR, Anderton BH, Brion J-P (2002) The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer’s disease. Acta Neuropathol 103:91–99. doi:10.1007/s004010100435 CrossRefPubMed

24.

Gong CX, Shaikh S, Wang JZ, Zaidi T, Grundke-Iqbal I, Iqbal K (1995) Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. J Neurochem 65:732–738CrossRefPubMed

25.

Lu PJ, Wulf G, Zhou XZ, Davies P, Lu KP (1999) The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature 399:784–788. doi:10.1038/21650 CrossRefPubMed

26.

Holler CJ, Davis PR, Beckett TL, Platt TL, Webb RL, Head E, Murphy MP (2014) Bridging Integrator 1 (BIN1) Protein Expression Increases in the Alzheimer’s Disease Brain and Correlates with Neurofibrillary Tangle Pathology - Journal of Alzheimer’s Disease - IOS Press. J Alzheimers Dis 42:1221–7. doi:10.3233/JAD-132450 PubMedCentralPubMed

27.

Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wölfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, Götz J (2010) Dendritic function of tau mediates amyloid-β toxicity in alzheimer’s disease mouse models. Cell 142:387–397. doi:10.1016/j.cell.2010.06.036 CrossRefPubMed

28.

Meunier B, Quaranta M, Daviet L, Hatzoglou A, Leprince C (2009) The membrane-tubulating potential of amphiphysin 2/BIN1 is dependent on the microtubule-binding cytoplasmic linker protein 170 (CLIP-170). Eur J Cell Biol 88:91–102. doi:10.1016/j.ejcb.2008.08.006 CrossRefPubMed

29.

Landrieu I, Lacosse L, Leroy A, Wieruszeski J-M, Trivelli X, Sillen A, Sibille N, Schwalbe H, Saxena K, Langer T, Lippens G (2006) NMR analysis of a Tau phosphorylation pattern. J Am Chem Soc 128:3575–83. doi:10.1021/ja054656+ CrossRefPubMed

30.

Lim WA, Richards FM, Fox RO (1994) Structural determinants of peptide-binding orientation and of sequence specificity in SH3 domains. Nature 372:375–379. doi:10.1038/372375a0 CrossRefPubMed

31.

Binder LI, Frankfurter A, Rebhun LI (1985) The distribution of tau in the mammalian central nervous system. J Cell Biol 101:1371–1378. doi:10.1083/jcb.101.4.1371 CrossRefPubMed

Title: Tau phosphorylation regulates the interaction between BIN1’s SH3 domain and Tau’s proline-rich domain
Authors: Yoann Sottejeau
Alexis Bretteville
François-Xavier Cantrelle
Nicolas Malmanche
Florie Demiaute
Tiago Mendes
Charlotte Delay
Harmony Alves Dos Alves
Amandine Flaig
Peter Davies
Pierre Dourlen
Bart Dermaut
Jocelyn Laporte
Philippe Amouyel
Guy Lippens
Julien Chapuis
Isabelle Landrieu
Jean-Charles Lambert
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: Acta Neuropathologica Communications / Issue 1/2015
Electronic ISSN: 2051-5960
DOI: https://doi.org/10.1186/s40478-015-0237-8

At a glance: The STEP trials

Springer Medicine

Tau phosphorylation regulates the interaction between BIN1’s SH3 domain and Tau’s proline-rich domain

Abstract

Introduction

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2015

The A673T mutation in the amyloid precursor protein reduces the production of β-amyloid protein from its β-carboxyl terminal fragment in cells

Cortical tau load is associated with white matter hyperintensities

IL-6 and Akt are involved in muscular pathogenesis in myasthenia gravis

Disease-related microglia heterogeneity in the hippocampus of Alzheimer’s disease, dementia with Lewy bodies, and hippocampal sclerosis of aging

Decreased mTOR signaling pathway in human idiopathic autism and in rats exposed to valproic acid

Interaction of prion protein with acetylcholinesterase: potential pathobiological implications in prion diseases